Results 51 to 60 of about 1,741 (166)

Therapeutic potential of a Bax inhibitor‐1/TMBIM6 antagonist (BIA) and its analogues in Aspergillus fumigatus‐induced asthma via dual targeting of AKT and epithelial‐derived inflammatory cytokines

British Journal of Pharmacology, EarlyView.
Background and Purpose Aspergillus fumigatus (A. fumigatus) exposure causes of severe allergic asthma, characterized by airway inflammation and epithelial dysfunction. TMBIM6 (Bax inhibitor‐1) has been implicated in airway epithelial stress responses and AKT signalling.
Young‐Jin Yu, Ahsan Ullah, Jisun Kim, Mehedi Hasan Bappi, Yerim Heo, Jin Hee Ahn, Hyun‐Kyoung Kim, Han‐Jung Chae   +7 more
wiley   +1 more source

Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series

Journal of Allergy and Clinical Immunology: Global
Tezepelumab, a mAb targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations in severe asthma. Four cases in which patients with severe asthma and chronic rhinosinusitis with nasal polyps showed improvements in both conditions after receiving ...
Shigesato Inoue, MD, Hiroaki Ogata, MD, PhD, Yoichi Dotake, MD, Koichi Takagi, MD, PhD, Ayaka Shiota, MD, Yumiko Ishii, MD, PhD, Kentaro Tanaka, MD, PhD, Keiko Kan-o, MD, PhD, Hiromasa Inoue, MD, PhD   +8 more
doaj   +1 more source

The National Allergy Centre of Excellence–Addressing Australia's Allergy Burden

Clinical &Experimental Allergy, EarlyView.
Australia's high allergy burden prompted a national response, leading to the establishment of the National Allergy Centre of Excellence (NACE) in 2022. The NACE has advanced research infrastructure, collaboration, and consumer‐centred care through four pillars, achieving global recognition and accelerating translation into policy, practice, and ...
A. Young, J. J. Koplin, D. E. Campbell, J. M. Davies, H. Edmund, T. Jamieson, C. J. Hornung, T. O'Farrell, D. West, E. Kayes, L. A. Gray, R. L. Peters, L. Gamble, K. Gwynne, J. Lee, M. Lucas, C. H. Katelaris, M. D. O'Sullivan, D. J. Palmer, J. Trubiano, S. van Nunen, S. L. Vale, T. Wanandy, K. P. Perrett   +23 more
wiley   +1 more source

Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps—Are We Comparing Apples With Oranges?

International Forum of Allergy &Rhinology, Volume 16, Issue 8, Page 769-777, August 2026.
Key Points In recent years, several biologics targeting Type 2 inflammation have been developed for treating chronic rhinosinusitis with nasal polyps (CRSwNP). These have been studied in registrational randomized controlled trials (RCTs), which vary in their patient populations, trial design, endpoints, geography, timing, or data‐handling processes ...
Marjolein Cornet, Peter W. Hellings, Martin Desrosiers, Martin Wagenmann, Richard Follows, Laura Walrave, Luz Adriana Jimenez, Lee Tombs, Dawn Edwards, Peter Howarth, Joseph K. Han   +10 more
wiley   +1 more source

Tezepelumab for asthma with current or previous smoking habit: Case series

Journal of Allergy and Clinical Immunology: Global
Tezepelumab effectively treated severe asthma in a current smoker and a former smoker, suggesting that thymic stromal lymphopoietin is involved in the pathogenesis of severe asthma in these patients. Tezepelumab may additionally be used for severe asthma
Yoshiro Kai, MD, PhD, Kentaro Suzuki, MD, Ryosuke Kataoka, MD   +2 more
doaj   +1 more source

Systemic Corticosteroids in the Management of Sinonasal Disease: An Evidence‐Based Expert Review

International Forum of Allergy &Rhinology, Volume 16, Issue 8, Page 852-879, August 2026.
ABSTRACT Background Chronic rhinosinusitis (CRS) is a prevalent, heterogeneous inflammatory disease associated with significant morbidity. Systemic corticosteroids (SCS) are commonly prescribed for their anti‐inflammatory effects, but cumulative exposure carries risks, including metabolic, cardiovascular, and skeletal complications.
Andrew Thamboo, Deanna Gigliotti, Eugenio De Corso, Stella Lee, Benjamin S. Bleier, Christopher J. Chin, Marie‐Noelle Corriveau, Valerie Hox, Claire Hopkins, Peter H. Hwang, Arif Janjua, Ludger Klimek, Daniel Lee, John Lee, Amber Luong, Geoffrey Mortuaire, Joaquim Mullol, Zara M. Patel, John Scott, Doron Sommer, Leigh Sowerby, Marc Tewfik, Beatrice Voizard, Martin Wagenmannm, Sarah K. Wise, Jonathan Yip, Quirina Thompson, Martin Desrosiers, Yvonne Chan   +28 more
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Three-dimensional bronchial tree visualization in exercise-induced severe asthma following tezepelumab treatment

Journal of Allergy and Clinical Immunology: Global
Airway hyperresponsiveness, a key feature of asthma, is associated with exercise-induced asthma. Tezepelumab was reported to reduce airway hyperresponsiveness.
Yoshiro Kai, MD, PhD, Yuichi Hishida, RT
doaj   +1 more source

Caecal Epithelium‐Derived Thymic Stromal Lymphopoietin is not Required for Protective Immunity Against Whipworm

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Immunity to Trichuris muris infection is unimpacted by epithelial knockout of TSLP expression. Imaging of transcription in the caecum reveals Tslp transcription throughout infection in EpCAM‐, Foxl1‐, Ccl24‐ lamina propria‐resident cells, contributing during the expulsion phase of infection. ABSTRACT Recent research examining classical type two alarmin
Connor P. Lynch, Seona Thompson, Erin‐Claire Pallott, Laura Campbell, Sang Hun Lee, Richard K. Grencis   +5 more
wiley   +1 more source

Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma

Journal of Asthma and Allergy, 2021
Sady Alpizar,1 Ayman Megally,2 Claudia Chen,3 Abhi Raj,4 John Downie,5 Gene Colice2 1Clinical Research Trials of Florida, Inc., Tampa, FL, USA; 2Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD,
Alpizar S, Megally A, Chen C, Raj A, Downie J, Colice G   +5 more
doaj